高级检索
当前位置: 首页 > 详情页

Functions of p53 in pluripotent stem cells

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越:梯队期刊

机构: [1]The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China [2]Center for Regenerative and Translational Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, TheSecond Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510632, China [3]Department of Biochemistry and Molecular Biology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou510080, China [4]Cancer Research Institute, Guangdong Provincial Key Laboratory of Tumor Immunotherapy, School of Basic MedicalSciences, Southern Medical University, Guangzhou 510515, China
出处:
ISSN:

关键词: p53 embryonic stem cells induced pluripotent stem cells genetic stability metabolism

摘要:
Pluripotent stem cells (PSCs) are capable of unlimited self-renewal in culture and differentiation into all functional cell types in the body, and thus hold great promise for regenerative medicine. To achieve their clinical potential, it is critical for PSCs to maintain genomic stability during the extended proliferation. The critical tumor suppressor p53 is required to maintain genomic stability of mammalian cells. In response to DNA damage or oncogenic stress, p53 plays multiple roles in maintaining genomic stability of somatic cells by inducing cell cycle arrest, apoptosis, and senescence to prevent the passage of genetic mutations to the daughter cells. p53 is also required to maintain the genomic stability of PSCs. However, in response to the genotoxic stresses, a primary role of p53 in PSCs is to induce the differentiation of PSCs and inhibit pluripotency, providing mechanisms to maintain the genomic stability of the self-renewing PSCs. In addition, the roles of p53 in cellular metabolism might also contribute to genomic stability of PSCs by limiting oxidative stress. In summary, the elucidation of the roles of p53 in PSCs will be a prerequisite for developing safe PSC-based cell therapy.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 1 区 生物
小类 | 1 区 细胞生物学
最新[2025]版:
大类 | 1 区 生物学
小类 | 1 区 细胞生物学
JCR分区:
出版当年[2018]版:
Q1 CELL BIOLOGY
最新[2023]版:
Q1 CELL BIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号